活化凝血酶原复合物与四因子凝血酶原复合物用于维生素K拮抗剂逆转的比较
本研究为回顾性多中心队列,纳入158例年龄大于18岁、因华法林相关出血接受活化凝血酶原复合物或四因子凝血酶原复合物的患者。活化凝血酶原复合物组(118例)国际标准化比值小于5者给500 IU、大于5者给1000 IU;四因子凝血酶原复合物组(40例)按美国食品药品监督管理局批准的剂量算法给药。四因子凝血酶原复合物组治疗前国际标准化比值更高(2.7±1.8 vs 3.5±2.9,p=0.0164),但治疗后国际标准化比值两组相似。控制治疗前国际标准化比值差异后,达到治疗后国际标准化比值小于1.4的能力无差异(比值比0.753,95%CI 0.637-0.890,p=0.0009);活化凝血酶原复合物组达到治疗后国际标准化比值小于1.2的比值比更高(比值比3.23,95%CI 1.34-7.81,p=0.0088)。仅报告1例治疗后血栓并发症。
要点
- 在因华法林相关出血接受逆转治疗的患者中,低固定剂量活化凝血酶原复合物(国际标准化比值小于5给500 IU,大于5给1000 IU)与标准剂量四因子凝血酶原复合物在治疗后国际标准化比值正常化方面效果相当。
- 四因子凝血酶原复合物组治疗前国际标准化比值高于活化凝血酶原复合物组(3.5±2.9 vs 2.7±1.8,p=0.0164),但治疗后国际标准化比值两组相似。
- 控制治疗前国际标准化比值差异后,达到治疗后国际标准化比值小于1.4的比值比为0.753(95%CI 0.637-0.890,p=0.0009),两组无差异。
- 活化凝血酶原复合物组达到治疗后国际标准化比值小于1.2的比值比为3.23(95%CI 1.34-7.81,p=0.0088),高于四因子凝血酶原复合物组。
- 仅报告1例治疗后血栓并发症,未观察到血栓事件增加。
适用人群与场景
- 年龄大于18岁、因华法林相关出血接受活化凝血酶原复合物或四因子凝血酶原复合物治疗的患者。
- 排除:因华法林相关出血以外指征接受任一药物的患者、孕妇、基线国际标准化比值小于2、按医院方案接受大量输血、因华法林相关出血接受血浆治疗、因急性华法林摄入接受治疗的患者。
处置流程与药物剂量
- 活化凝血酶原复合物组(来自一家医院):国际标准化比值小于5者给500 IU,国际标准化比值大于5者给1000 IU。
- 四因子凝血酶原复合物组(来自另一家医院):按美国食品药品监督管理局批准的剂量算法给药。
研究设计与关键结果
- 研究类型:回顾性多中心队列;共纳入158例患者(活化凝血酶原复合物组118例,四因子凝血酶原复合物组40例)。
- 四因子凝血酶原复合物组治疗前国际标准化比值高于活化凝血酶原复合物组(3.5±2.9 vs 2.7±1.8,p=0.0164),但治疗后国际标准化比值两组相似。
- 控制治疗前国际标准化比值差异后,达到治疗后国际标准化比值小于1.4的比值比为0.753(95%CI 0.637-0.890,p=0.0009),两组无差异。
- 活化凝血酶原复合物组达到治疗后国际标准化比值小于1.2的比值比为3.23(95%CI 1.34-7.81,p=0.0088),高于四因子凝血酶原复合物组。
- 仅报告1例治疗后血栓并发症。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,低固定剂量活化凝血酶原复合物在逆转华法林相关出血时,国际标准化比值正常化效果与标准剂量四因子凝血酶原复合物相当,且未观察到血栓事件增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the international normalized ratio normalization efficacy of activated prothrombin complex concentrates and 4-factor prothrombin complex concentrates and to evaluate the thrombotic complications in patients treated with these products for warfarin-associated hemorrhage.
DESIGN: Retrospective, Multicenter Cohort.
SETTING: Large, Community, Teaching Hospital.
PATIENTS: Patients greater than 18 years old and received either activated prothrombin complex concentrate or 4-factor prothrombin complex concentrate for the treatment of warfarin-associated hemorrhage. We excluded those patients who received either agent for an indication other than warfarin-associated hemorrhage, pregnant, had a baseline international normalized ratio of less than 2, received a massive transfusion as defined by hospital protocol, received plasma for treatment of warfarin-associated hemorrhage, or were treated for an acute warfarin ingestion.
INTERVENTIONS: Patients in the activated prothrombin complex concentrate group (enrolled from one hospital) with an international normalized ratio of less than 5 received 500 IU and those with an international normalized ratio greater than 5 received 1,000 IU. Patients in the 4-factor prothrombin complex concentrate (enrolled from a separate hospital) group received the Food and Drug Administration approved dosing algorithm.
MEASUREMENTS AND MAIN RESULTS: A total of 158 patients were included in the final analysis (activated prothrombin complex concentrate = 118; 4-factor prothrombin complex concentrate = 40). Those in the 4-factor prothrombin complex concentrate group had a higher pretreatment international normalized ratio (2.7 ± 1.8 vs 3.5 ± 2.9; p = 0.0164). However, the posttreatment international normalized ratio was similar between the groups. In addition, even when controlling for differences in the pretreatment international normalized ratio, there was no difference in the ability to achieve a posttreatment international normalized ratio of less than 1.4 (odds ratio, 0.753 [95% CI, 0.637-0.890]; p = 0.0009). Those in the activated prothrombin complex concentrate group did have higher odds of achieving a posttreatment international normalized ratio of less than 1.2 (odds ratio, 3.23 [95% CI, 1.34-7.81]; p = 0.0088). There was only one posttreatment thrombotic complication reported.
CONCLUSIONS: A low, fixed dose of activated prothrombin complex concentrate was as effective as standard dose 4-factor prothrombin complex concentrate for normalization of international normalized ratio. In addition, we did not see an increase in thrombotic events.
参考来源
- Rowe AS, Dietrich SK, Phillips JW, et al. Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist Reversal. Crit Care Med. 2018. PMID: 29498942. doi:10.1097/CCM.0000000000003090
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。